Mentice has received a €1,062,750 EUR order for simulation solutions from a top 20 global MedTech company
Read more
Mentice Q3-2024 Interim Report earnings call
Join live

Mentice publishes the company’s interim report for the period April - June 2024

Tuesday, July 23, 2024

Net sales reaching over 100 msek and the EBITDA of 24.5 msek is the highest in the company’s history

SIGNIFICANT EVENTS DURING THE SECOND QUARTER 2024 (APR – JUN)

  • Larger repeat industry order to significant client of 2.2 MUSD was announced in May.
  • CEO Göran Malmberg decided to step down from his position at the end of the year. The recruitment of a successor has been initiated. The plan for Malmberg is to step into an advisor role coming into 2025.


SECOND QUARTER 2024 (APR - JUN)

  • Order intake amounted to 71 (77) MSEK, a decrease of -8%.
  • Net sales amounted to 101 (74) MSEK, an increase of 36%, whereof 34% organic, 1% acquired and 1% currency effect.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 24.5 (10.7) MSEK.
  • Net income for the period amounted to 17.2 (1.5) MSEK.
  • Earnings per share (EPS) were 0.67 (0.06) SEK.
  • Cash flow from operating activities amounted to 5.3 (5.2) MSEK.


SIX MONTHS 2024 (JAN - JUN)

  • Order intake amounted to 109 (135) MSEK, a decrease of -19%.
  • The order book by the end of the period was 114 (125) MSEK, a decrease of -9%.
  • Net sales amounted to 146 (139) MSEK, an increase of 5%, whereof 4% organic, 1% acquired and 0% currency effect.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 6.1 (17.9) MSEK.
  • Net income for the period amounted to -7.4 (0.0) MSEK.
  • Earnings per share (EPS) were -0.29 (0.0) SEK.
  • Cash flow from operating activities amounted to 7.2 (2.5) MSEK.

Webcast presentation of the interim report
Date: July 23, 2024
Time: 10:00 CEST

To join the presentation, please visit https://investor.mentice.com/


Mentice får en order på simuleringslösningar värd €1,062,750 EUR från ett topp 20 globalt medtech bolag
Läs Mer
Mentice Q3-2024 Delårsrapport webcast
Se livestream

Mentice publishes the company’s interim report for the period April - June 2024

Tuesday, July 23, 2024

Net sales reaching over 100 msek and the EBITDA of 24.5 msek is the highest in the company’s history

SIGNIFICANT EVENTS DURING THE SECOND QUARTER 2024 (APR – JUN)

  • Larger repeat industry order to significant client of 2.2 MUSD was announced in May.
  • CEO Göran Malmberg decided to step down from his position at the end of the year. The recruitment of a successor has been initiated. The plan for Malmberg is to step into an advisor role coming into 2025.


SECOND QUARTER 2024 (APR - JUN)

  • Order intake amounted to 71 (77) MSEK, a decrease of -8%.
  • Net sales amounted to 101 (74) MSEK, an increase of 36%, whereof 34% organic, 1% acquired and 1% currency effect.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 24.5 (10.7) MSEK.
  • Net income for the period amounted to 17.2 (1.5) MSEK.
  • Earnings per share (EPS) were 0.67 (0.06) SEK.
  • Cash flow from operating activities amounted to 5.3 (5.2) MSEK.


SIX MONTHS 2024 (JAN - JUN)

  • Order intake amounted to 109 (135) MSEK, a decrease of -19%.
  • The order book by the end of the period was 114 (125) MSEK, a decrease of -9%.
  • Net sales amounted to 146 (139) MSEK, an increase of 5%, whereof 4% organic, 1% acquired and 0% currency effect.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 6.1 (17.9) MSEK.
  • Net income for the period amounted to -7.4 (0.0) MSEK.
  • Earnings per share (EPS) were -0.29 (0.0) SEK.
  • Cash flow from operating activities amounted to 7.2 (2.5) MSEK.

Webcast presentation of the interim report
Date: July 23, 2024
Time: 10:00 CEST

To join the presentation, please visit https://investor.mentice.com/